Michael T Milano

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Cancer Treat Rev 37:567-78. 2011
  2. ncbi Normal tissue tolerance dose metrics for radiation therapy of major organs
    Michael T Milano
    Department of Radiation Oncology and James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Semin Radiat Oncol 17:131-40. 2007
  3. pmc Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Clin Oncol 28:5088-96. 2010
  4. doi Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients
    Michael T Milano
    Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer 117:5538-47. 2011
  5. doi Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 83:878-86. 2012
  6. doi Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
    Int J Radiat Oncol Biol Phys 72:1516-22. 2008
  7. doi Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiother Oncol 91:301-6. 2009
  8. doi Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, P O Box 647, Rochester, NY 14642, USA
    Breast Cancer Res Treat 115:601-8. 2009
  9. doi Split-course palliative radiotherapy for advanced non-small cell lung cancer
    Su K Metcalfe
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    J Thorac Oncol 5:185-90. 2010
  10. doi Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Head Neck 34:1782-8. 2012

Collaborators

Detail Information

Publications50

  1. doi Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Cancer Treat Rev 37:567-78. 2011
    ..The impact of dose, volume, fractionation, and other relevant clinic-pathologic variables are discussed, as are limitations of the published data...
  2. ncbi Normal tissue tolerance dose metrics for radiation therapy of major organs
    Michael T Milano
    Department of Radiation Oncology and James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Semin Radiat Oncol 17:131-40. 2007
    ..This review summarizes the published clinical data on the risk of late toxicity as a function of quantitative dose metrics and attempts to offer suggested dose constraints for radiation treatment planning...
  3. pmc Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Clin Oncol 28:5088-96. 2010
    ..However, there are no large population-based studies that describe overall survival (OS) and cause-specific survival (CSS) compared with women with first primary BC...
  4. doi Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients
    Michael T Milano
    Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer 117:5538-47. 2011
    ..However, no population-based studies have compared overall survival (OS) between HL survivors who developed nonsmall cell lung cancer (HL-NSCLC) versus patients with first primary NSCLC (NSCLC-1)...
  5. doi Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 83:878-86. 2012
    ..To analyze the long-term survival and tumor control outcomes after stereotactic body radiotherapy (SBRT) for metastases limited in number and extent...
  6. doi Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
    Int J Radiat Oncol Biol Phys 72:1516-22. 2008
    ..To characterize oligometastases in patients enrolled on two prospective pilot studies, treating oligometastases with hypofractionated stereotactic body radiotherapy and stereotactic radiosurgery to cranial lesions...
  7. doi Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiother Oncol 91:301-6. 2009
    ..To investigate the toxicity and outcome after moderately hypofractionated stereotactic body radiotherapy (SBRT) for central thoracic lesions...
  8. doi Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, P O Box 647, Rochester, NY 14642, USA
    Breast Cancer Res Treat 115:601-8. 2009
    ..Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer...
  9. doi Split-course palliative radiotherapy for advanced non-small cell lung cancer
    Su K Metcalfe
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    J Thorac Oncol 5:185-90. 2010
    ..Albeit an important subject, there is a lack of consensus for an optimal palliative RT regimen. We report the outcomes of a split-course palliative chest RT, a frequently used schema at our institution...
  10. doi Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Head Neck 34:1782-8. 2012
    ..Patients with head and neck squamous cell cancer (HNSCC) are at risk of developing second primary lung cancer (SPLC)...
  11. pmc Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer
    Praveena Cheruvu
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York, USA
    Radiat Oncol 6:80. 2011
    ..We hypothesized that patients treated with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for Stage III NSCLC...
  12. doi Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 78:1147-55. 2010
    ..To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation...
  13. doi Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 647, Rochester, NY 14642, USA
    J Neurooncol 98:83-92. 2010
    ..Given the retrospective nature of this study, specific recommendations about which situations warrant radiotherapy cannot be determined...
  14. doi Definitive radiotherapy for stage I nonsmall cell lung cancer: a population-based study of survival
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer 118:5572-9. 2012
    ....
  15. doi Spurious progression in pediatric brain tumors
    Sheema Chawla
    Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave Box 647, Rochester, NY 14642, USA
    J Neurooncol 107:651-7. 2012
    ..Therefore, SP occurs more commonly in children with low grade tumors, but can also occur with high grade brain tumors, regardless of therapeutic approach...
  16. doi Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma
    Rajiv Mangla
    Department of Imaging Sciences, University of Rochester Medical Center, 601 Elmwood Ave, PO Box 648, Rochester, NY 14642 8648, USA
    Radiology 256:575-84. 2010
    ....
  17. doi Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 73:832-7. 2009
    ..We hypothesized that these patients would remain amenable to curative-intent treatment with additional RT courses...
  18. pmc Normal tissue toxicity after small field hypofractionated stereotactic body radiation
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiat Oncol 3:36. 2008
    ..While clinical data has shown SBRT to be safe in most circumstances, more data is needed to refine the ideal dose-volume metrics...
  19. doi Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Am J Clin Oncol 33:157-63. 2010
    ....
  20. doi Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation
    Alan W Katz
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 83:895-900. 2012
    ..We also examined histological response to radiation in the resected or explanted livers...
  21. doi Impact of radiotherapy on laryngeal cancer survival: a population-based study of 13,808 US patients
    Hong Zhang
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642 8647, USA
    Cancer 118:1276-87. 2012
    ..However, the impact of radiation on overall survival (OS) in a large population-based study has not been evaluated to date...
  22. ncbi Stereotactic Body Radiation Therapy (SBRT) for lung metastases
    Paul Okunieff
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
    Acta Oncol 45:808-17. 2006
    ..Median survival time and progression-free survival both appear better than that achieved with standard care alone. Long-term progression-free survival can be seen in a subset of patients when all tumors are targeted...
  23. doi Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival
    Sughosh Dhakal
    Department of Radiation Oncology, University of Rochester, Rochester, NY, USA
    Int J Radiat Oncol Biol Phys 82:940-5. 2012
    ..Since 2001, we have treated PM with stereotactic body radiation therapy (SBRT). We postulated that SBRT for PM from STS would yield excellent local control (LC) and overall survival (OS)...
  24. doi Stereotactic body radiotherapy for treatment of adrenal metastases
    Sheema Chawla
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 75:71-5. 2009
    ..To investigate the dosimetry and outcomes of patients undergoing stereotactic body radiotherapy (SBRT) for metastases to the adrenal glands...
  25. doi Stereotactic radiosurgery for spinal metastases: case report and review of treatment options
    Sheema Chawla
    University of Rochester Medical Center, Department of Radiation Oncology, 601 Elmwood Ave Box 647, Rochester, NY 14642, USA
    Bone 45:817-21. 2009
    ..We also review the literature on treatment of spinal metastases using SRS, SBRT, and other modalities...
  26. ncbi A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer 112:650-8. 2008
    ..It is hypothesized that oligometastatic disease represents a state of potentially curable, limited metastases. Stereotactic body radiation therapy (SBRT) is an option for patients who are not amenable to or do not want resection...
  27. doi Incidental brain lesions in children: to treat or not to treat?
    Amy Lee Bredlau
    University of Rochester, Rochester, NY 14642, USA
    J Neurooncol 106:589-94. 2012
    ..The outcome for children with such lesions is excellent. Close monitoring of these patients with serial MRIs may be a safe alternative to immediate biopsy and/or resection for select patients...
  28. ncbi Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases
    Alan W Katz
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 67:793-8. 2007
    ..To evaluate the feasibility and efficacy of hypofractionated stereotactic body radiation therapy (SBRT) for the treatment of liver metastases...
  29. doi Malignant pleural mesothelioma: a population-based study of survival
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Thorac Oncol 5:1841-8. 2010
    ..This study characterizes the overall survival (OS) and variables affecting OS in patients with malignant pleural mesothelioma...
  30. doi Stereotactic body radiation for the spine: a review
    Sheema Chawla
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY
    Am J Clin Oncol 36:630-6. 2013
    ....
  31. doi Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes
    Rajiv Mangla
    Department of Imaging Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Neurooncol 116:325-31. 2014
    ..0009). Pre-treatment rCBV may serve as a prognostic imaging biomarker for anaplastic astrocytomas, but not grade III oligodendroglioma tumors...
  32. doi Second course of radiation for new primary head-and-neck cancer: population-based study of survival
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, NY, USA
    Am J Clin Oncol 34:367-71. 2011
    ..To analyze patient and tumor characteristics, and survival of patients who received 2 courses of radiotherapy for different primary head and neck cancers (HNCs)...
  33. pmc Stereotactic radiosurgery for glioblastoma: retrospective analysis
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiat Oncol 4:11. 2009
    ..This retrospective study was done to better understand the conditions for which stereotactic radiosurgery (SRS) for glioblastoma may be efficacious...
  34. ncbi New prospects for management and treatment of inoperable and recurrent skull base meningiomas
    Mahlon D Johnson
    Department of Pathology and Laboratory Medicine, Division of Neuropathology, University of Rochester Medical Center, 601 Elmwood Ave Box 626, Rochester, NY 14623, USA
    J Neurooncol 86:109-22. 2008
    ..This article reviews some recent findings pathways that appear to regulate meningioma growth. Potential targets for novel therapies are also discussed...
  35. doi Second primary head and neck cancer after Hodgkin lymphoma: A population-based study of 44,879 survivors of Hodgkin lymphoma
    Amit K Chowdhry
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York
    Cancer 121:1436-45. 2015
    ..Survivors of Hodgkin lymphoma (HL) are at an increased risk of developing second malignancies. To the authors' knowledge, the risks of head and neck cancer (HNC) after HL and subsequent survival have not been thoroughly investigated...
  36. pmc Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study
    Chunkit Fung
    Chunkit Fung, Michael T Milano, and Lois B Travis, University of Rochester Medical Center, Rochester, NY and Sophie D Fossa and Jan Oldenburg, Norwegian Radium Hospital, Oslo, Norway
    J Clin Oncol 31:3807-14. 2013
    ..We quantified the site-specific risk of solid cancers among testicular nonseminoma patients treated in the modern era of cisplatin-based chemotherapy, without radiotherapy...
  37. pmc Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients
    Michael T Milano
    Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, NY 14642, USA
    J Thorac Dis 4:22-9. 2012
    ..To date, no population-based study has analyzed prognostic variables for overall survival (OS) among HL survivors who developed non-small cell lung cancer (NSCLC)...
  38. doi Radiation therapy in the management of patients with limited brain metastases
    Sughosh Dhakal
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY
    Am J Clin Oncol 37:208-14. 2014
    ..In this review, we summarize the evolving role of radiotherapy in the management of brain metastases and then discuss the issues related to neurotoxicity from radiation and future areas of investigation. ..
  39. doi Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients
    Paul Youn
    Department of Radiation Oncology and Rubin Center for Cancer Survivorship, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York
    Cancer 120:2334-42. 2014
    ....
  40. doi The integration of cancer survivorship training in the curriculum of hematology/oncology fellows and radiation oncology residents
    Michelle Shayne
    University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY, 14642, USA
    J Cancer Surviv 8:167-72. 2014
    ..Training programs currently focus on treatment, while survivorship care focuses on time after treatment. Cancer survivorship training represents an education paradigm shift...
  41. doi Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women
    Michael T Milano
    Department of Radiation Oncology and Rubin Center for Cancer Survivorship and Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, NY
    J Thorac Oncol 9:1081-90. 2014
    ..Annually, 1.4 million women worldwide are diagnosed with breast cancer (BC) and are at risk for another common malignancy: non-small-cell lung cancer (NSCLC). No large population-based study has examined subsequent survival...
  42. pmc Thoracic malignant solitary fibrous tumors: A population-based study of survival
    Michael T Milano
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Thorac Dis 3:99-104. 2011
    ..This study characterizes the overall survival (OS) and cause specific survival (CSS) of patients with thoracic malignant solitary fibrous tumors...
  43. ncbi Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    Int J Radiat Oncol Biol Phys 64:382-91. 2006
    ....
  44. ncbi Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
    Michael T Milano
    Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 28:1141-51. 2006
    ..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques...
  45. ncbi Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 59:445-53. 2004
    ..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies...
  46. ncbi Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 63:354-61. 2005
    ..To assess survival, local control, and toxicity of intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the anal canal...
  47. ncbi Intensity-modulated radiotherapy and the Internet
    David A Schomas
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 101:412-20. 2004
    ..The objective of the current study was to evaluate the content and quality of patient-oriented information regarding intensity-modulated radiotherapy (IMRT) on the Internet...
  48. ncbi Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity
    Ashesh B Jani
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Urology 67:147-51. 2006
    ..To provide a single-institution analysis of the influence of pelvic intensity-modulated radiotherapy (RT) on acute genitourinary (GU) and gastrointestinal (GI) toxicity...
  49. ncbi Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer
    Joseph K Salama
    Departments of Radiation and Cellular Oncology, University of Chicago, 5758 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Cancer J 11:140-6. 2005
    ..A phase I study was conducted to determine the maximum tolerated dose and dose-limiting toxicities of this regimen...
  50. ncbi Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
    ..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck...